retatrutide eli lilly press release 2024 2025 Obesity Wins Recast And Foundayo As Cardiometabolic Story Lilly's triple-acting obesity drug hits

No, you do not measure mL yourself

Research continues to examine how treatment duration and medication dose affect eye complication rates

The emphasis on early combination therapyparticularly SGLT2 inhibitors and GLP-1/GIP agentssignals a more proactive, risk-based approach rather than reactive intensification

So, if someone gained weight and then started taking GLP-1 agonist medications, the end result result may not be exactly what that person looked like previously

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B

And that turned out to be a very positive outcome